Wire · opportunities
Roche's next big breast cancer drug, Wilserdly, secures FDA approval as 4th oral SERD
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 November 2026 · Fusion42 review
Roche's oral SERD drug Wilserdly (giredestrant) has won FDA approval for use in combination with everolimus for HR-positive, HER2-negative, ESR1-mutated advanced breast cancer. The approval marks Wilserdly as the fourth oral SERD available, competing in a niche second-line setting, while Roche awaits a crucial upcoming FDA decision on its use in the larger adjuvant early-stage breast cancer market.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 16 Nov 2026 and 17 Nov 2026.
◆ ◆ The Wire takeaway
Your breast cancer drug efforts face a competitive FDA landscape demanding differentiation through adjuvant trials, not just second-line approvals. Watch Roche's pending adjuvant FDA decision as it will open a far larger patient market and reset commercial priorities.
◆ Coverage
5 sources · first reported 16 Nov 2026 · latest 17 Nov 2026
◆ Related on Wire
◆ Topics